A Path to Wellness: Exploring Hypertrophic Cardiomyopathy Therapeutics
The hypertrophic cardiomyopathy therapeutics market was estimated at USD 1.3 billion in 2020 and is likely to grow at a CAGR of 2.4% during 2021-2026 to reach USD 1.49 billion in 2026.
Hypertrophic cardiomyopathy is referred to as a disorder where the heart muscle becomes abnormally thick or hypertrophied. The thickened heart muscle then causes the heart to be ineffective in pumping blood. This disease usually goes undiagnosed as many people with the disease have no or lesser symptoms. The therapies to treat HCM include beta-blockade and verapamil alone or in combination.